Clinicalopathological evaluation of soft tissue myxofibrosarcoma
Abstract
Purpose: The aim of this study is to evaluate the relationship between the clinical course of these tumors by emphasizing the epidemiological data as well as the pathological features of different myxofibrosarcoma cases.
Materials and Methods: 22 cases of myxofibrosarcoma were included in the single center study. Age, gender, tumor location, size, histopathological features as well as treatment modalities and clinical follow-up of the cases were also evaluated. Additional immunohistochemical studies were applied for the differential diagnosis in pathological evaluation.
Results: The mean age of the patients was 54 years old and there is no sex predilection. The extremities are the most common location. Deep located myxofibrosarcoma were highly aggressive unlike superficial counterparts. The grade given as a result of pathological examination is closely related to the clinical course. Since the mean recurrence period is 16 months, long term follow up is required. Recurrence is present in all metastatic cases. Death from the disease occurred only in those with a higher grade.
Conclusion: Myxofibrosarcomas are rarely seen but diagnostically challenging. Accurate diagnosis is essential to differentiate myxofibrosarcoma from other pleomorphic sarcomas, and to manage the treatment of patients since it may mimic even reactive lesions by histopathologically. Superficial and low grade myxofibrosarcoma of present study showed excellent prognosis and it has been presented as a contribution to the literature that these patients may have a good prognosis with correct diagnosis and treatment.
Kaynakça
- 1 Lurkin A, Ducimetiere F, Vince DR, et al. Epidemiological evaluation of concordance between initial diagnosis and central pathology review in a comprehensive and prospective series of sarcoma patients in the Rhone- Alpes region. BMC Cancer. 2010;10:150.
- 2 S.W. Weiss, F.M. Enzinger, Myxoid variant of malignant fibrous histiocytoma,Cancer 39 (1977) 1672–1685.
- 3 Fletcher C.D.M., Bridge J.A., Hogendoorn P.C.W., Mertens F. WHO Classification of Tumours of Soft Tissue and Bone. Pathology and Genetics of Tumours of Soft Tissue and Bone (4th), IARC Press, Lyon (2013)
- 4 Sambri, A., Bianchi, G., Righi, A., Ferrari, C., & Donati, D. (2016). Surgical margins do not affect prognosis in high grade myxofibrosarcoma. European Journal of Surgical Oncology (EJSO), 42(7), 1042–1048. doi:10.1016/j.ejso.2016.05.015
- 5 Baheti AD, Tirumani SH, Rosenthal MH, Howard SA, Shinagare AB, Ramaiya NH, et al. Myxoid soft-tissue neoplasms: comprehensive update of the taxonomy and MRI features. AJR Am J Roentgenol. 2015; 204(2) : 374 -85.
- 6 Gronchi A, Lo Vullo S, Colombo C, et al. Extremity soft tissue sarcoma in a series of patients treated at a single institution: local control directly impacts survival. Ann Surg 2010;251:506–11.
- 7 Fletcher CD, Gustafson P, Rydholm A, Willen H, Akerman M. Clinicopathologic re-evaluation of 100 malignant fibrous histiocytomas: prognostic relevance of subclassification. J Clin Oncol 2001;19: 3045–50.
- 8 Mentzel T, van den Berg E, Molenaar W. Myxofibrosarcoma In: Fletcher C, Unni K, Mertens F, editors. WHO classification of tumors-pathology and genetics, tumors of soft tissue and bone. Lyon: IARC Press; 2002. p. 102-103.
- 9 Fletcher CDM, Hogendoorm PCW, Mertens F, Bridge J, eds. WHO Classification of Tumors of Soft Tissue and Bone. Lyon, France: IARC Press: 2013.
- 10 Odei B, Rwigema JC, Eilber FR, Eilber FC, Selch M, Singh A, Chmielowski B, Nelson SD, Wang PC, Steinberg M, Kamrava M.Predictors of Local Recurrence in Patients With Myxofibrosarcoma.Am J Clin Oncol. 2018 Sep;41(9):827-831. doi: 10.1097/COC.0000000000000382.
